AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$SOLV

Solventum Corporation GAAP EPS of -$0.07 misses by $0.28, revenue of $1.94B beats by $10M (SOLV:NYSE)

Solventum Corporation reported Q3 GAAP EPS of -$0.07, missing estimates by $0.28, while revenue of $1.94B beat expectations by $10M, down 7.6% year-over-year. The company is exploring offers for its Health Information Systems Business.

Original reporting
seekingalpha.com
Published Nov 5, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SOLV
Bearish
high confidence
Mentioned
$SOLV
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SOLVBearishHigh
01

Why it matters

The earnings miss may trigger short‑term selling pressure, while the revenue beat could soften the decline.

02

Market read

First‑report earnings data for SOLV, likely to move the stock in after‑hours trading.

03

What to watch

One‑time charges or accounting adjustments may have driven the EPS miss.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Solventum Corporation released its Q3 2026 earnings, reporting a GAAP EPS miss and a modest revenue beat.

Company-level read

Ticker impact

$SOLVBearishHigh confidence
Context

Q3 GAAP EPS of -$0.07 missed expectations by $0.28 and revenue of $1.94B beat estimates by $10M.

Expected impact

likely downside as market prices in the earnings miss

Evidence & confidence

The EPS miss is material and the first report of the quarter's results, prompting immediate trader reaction.

Market effects

Sector

Healthcare information systems sector may see broader scrutiny of earnings quality.

Regional

U.S. market participants may adjust exposure to mid‑cap healthcare stocks.

Global

Limited; primarily affects U.S. investors focused on the ticker.

Counterpoint

What could challenge this read

The revenue beat could signal underlying growth despite the EPS miss.

Key entities

  • company
    Solventum Corporation

    U.S.-listed healthcare information systems provider (ticker SOLV).

Read at source← All news

StorySolventum posts Q3 loss, raises full‑year EPS guidance to $7.20‑$7.30

Also covered by

5 outlets

Related articles

$SOLVMedAI 8/10

SOLV Energy Q3 Revenue Rises 65% to $1.24 Billion; Raises 2026 Guidance

SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, with net income of $123M. Adjusted EBITDA was $173M, and gross margin was 17.8%. The company raised its 2026 guidance for revenue, adjusted gross profit, and adjusted EBITDA. Growth was driven by new construction and existing infrastructure revenue. SOLV completed its acquisition of ASB Energy Services in October 2026.

tradingview.com
$SOLVMed

Solventum (SOLV) stock trades up, here is why

Solventum (SOLV) shares rose 5% after reporting Q3 2026 revenue of $1.95B and EPS of $1.45, and raising full-year EPS guidance to $7.20-$7.30. The company completed ERP cutovers and exited 90% of transition agreements with 3M. Shares cooled to $91.19, up 4.6% from the previous close.

finance.yahoo.com
$SOLVMed

Solventum Q3 Earnings Call Highlights

Solventum reported Q3 sales of $1.9B, with mixed performance across segments. Gross margin rose to 57.1%, while operating margin fell to 19.9%. The company raised its full-year earnings outlook to $7.20-$7.30 per share and expects high-end organic sales growth. It also announced plans to separate its Health Information Systems business and renegotiated a raw material supply agreement with 3M.

finance.yahoo.com
MedAI 8/10

Solventum Earnings Call Signals Stronger Growth Ahead

Solventum Corporation (SOLV) reported Q3 earnings, highlighting strong execution despite ERP transition challenges. Sales were $1.95B, down 7% YoY, but organic growth was ~4% excluding ERP timing reversals. Gross margin rose to 57.1%, and full-year EPS guidance was raised to $7.20-$7.30. The 3M separation is 90% complete, with margin expansion and cost savings driving growth.

theglobeandmail.com